Definitive Contract 75A50120C00034
Award Date
4/3/20
Potential Completion Date
6/15/25
Potential Value
$1.8B
Awardee
Modernatx, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This definitive contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Moderna US, Inc. for COVID-19 vaccinations in support of the 2022 Fall Vaccine Campaign. The $7.8 billion firm fixed price contract is a transfer from the original awarding agency, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and represents continuation of vaccine production...
This is a definitive contract awarded by the Joint Program Executive Office for Chemical and Biological Defense, a Defense Department agency, to Moderna, Inc. for 100 million doses of the SARS-CoV-2 mRNA-1273 vaccine. The $8.2 billion firm fixed price contract has an ultimate completion date of August 10, 2023. Moderna, a manufacturer of pharmaceutical goods, has previously received prime and subcontract awards from various government agencies including the Department of Veterans Affairs,...
This is a definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS), to Modernatx, Inc. The $81,397,873.67 cost-plus-fixed-fee contract is to advance the development of a messenger RNA (mRNA) vaccine for the prevention of Zika virus. The contract has a completion date of July 1, 2024. Modernatx, Inc. is a for-profit manufacturer of pharmaceutical goods that has provided...
<p>The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense (DOD - Army - USASC) awarded a Definitive Contract valued at $7,837,399,999.00 to Moderna US, Inc. Moderna US Inc. Division for COVID-19 MRNA Vaccines. The place of performance will be in Cambridge, MA 02139, USA and the period of performance is from July 28, 2022 through March 31, 2023. The pricing structure is Firm Fixed Price.</p>
This is a $65,806,649.98 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Biofactura Inc. for preclinical and manufacturing development activities. The contract includes cell line development, process development, non-clinical efficacy and safety studies, manufacturing, and clinical activities. The contract was awarded on September 26, 2019 with an ultimate completion date of March 30, 2029. The contract has no...
<p>This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Modex Therapeutics, Inc. to advance the development of potent, cross-reactive multispecific antibodies for the preparedness countermeasure of COVID-19 and seasonal and highly pathogenic avian influenza. The contract has an ultimate completion date of January 18, 2030. This award is not a set-aside contract.</p>
This is a $8,650,565,549.53 Firm Fixed Price definitive contract awarded to Pfizer Inc. by the Office of the Assistant Secretary for Preparedness and Response (ASPR) for the provision of COVID-19 vaccines. The contract has an ultimate completion date of May 29, 2024 and was awarded on October 1, 2022 without any set-aside designation. Pfizer, a global pharmaceutical manufacturer, is the prime contractor for this award. The contract supports the government's COVID-19 vaccine initiatives and is...
This is a $918,380,272.80 definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Phlow Corp, a for-profit pharmaceutical manufacturer, to provide U.S.-based advanced manufacturing of COVID-19 essential medicines and responses to future threats. The contract has a 10-year period of performance ending in May 2030 and uses a cost-plus-fixed-fee pricing structure. The award is funded under ASPR's...
This is a $37,000 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Protein Sciences Corp, a for-profit manufacturer, to provide purified recombinant proteins. The contract has no set-aside designation. Protein Sciences Corp has received multiple federal contract awards from HHS's Office of the Assistant Secretary for Preparedness and Response...
This is a $228,598,975.00 definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC. The contract was issued under ASPR's Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and...